Equity

BGF World Healthscience Fund

Overview

Important Information: Capital at Risk. The value of investments and the income from them can fall as well as rise and are not guaranteed. Investors may not get back the amount originally invested.

Investment risk is concentrated in specific sectors, countries, currencies or companies. This means the Fund is more sensitive to any localised economic, market, political, sustainability-related or regulatory events. The value of equities and equity-related securities can be affected by daily stock market movements. Other influential factors include political, economic news, company earnings and significant corporate events. Active management of currency exposure through derivatives may make the Fund more sensitive to changes in foreign exchange rates. If the currency exposures against which the Fund is hedged appreciates investors may not benefit from such appreciation. The Fund seeks to exclude companies engaging in certain activities inconsistent with ESG criteria. Investors should therefore make a personal ethical assessment of the Fund’s ESG screening prior to investing in the Fund. Such ESG screening may adversely affect the value of the Fund’s investments compared to a fund without such screening.

All currency hedged share classes of this fund use derivatives to hedge currency risk. The use of derivatives for a share class could pose a potential risk of contagion (also known as spill-over) to other share classes in the fund. The fund’s management company will ensure appropriate procedures are in place to minimise contagion risk to other share class. Using the drop down box directly below the name of the fund, you can view a list of all share classes in the fund – currency hedged share classes are indicated by the word “Hedged” in the name of the share class. In addition, a full list of all currency hedged share classes is available on request from the fund’s management company

To the extent the Fund undertakes securities lending to reduce costs, the Fund will receive 62.5% of the associated revenue generated and the remaining 37.5% will be received by BlackRock as the securities lending agent. As securities lending revenue sharing does not increase the costs of running the Fund, this has been excluded from the ongoing charges.

Loading

Performance

Performance

Chart

View full chart
Chart
Bar chart with 2 data series.
The chart has 1 X axis displaying categories.
The chart has 1 Y axis displaying Values. Range: -10 to 30.
End of interactive chart.
During this period performance was achieved under circumstances that no longer apply
*On 30/Aug/2022, the Fund changed its name and/or investment objective and policy..
  2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Total Return (%) -5.3 25.3 6.5 24.4 15.5 16.9 -5.3 -1.0 -1.1
Constraint Benchmark 1 (%) -6.8 19.8 2.5 23.2 13.5 19.8 -5.4 3.8 1.1

Performance is shown after deduction of ongoing charges. Any entry and exit charges are excluded from the calculation.

  1y 3y 5y 10y Incept.
-1.05 -2.45 4.63 - 6.57
Constraint Benchmark 1 (%)

as of 31/Dec/2024

1.13 -0.25 6.18 - 6.26
  YTD 1m 3m 6m 1y 3y 5y 10y Incept.
-1.05 -5.87 -10.54 -9.28 -1.05 -7.18 25.40 - 82.59
Constraint Benchmark 1 (%)

as of 31/Dec/2024

1.13 -6.09 -11.40 -6.35 1.13 -0.75 34.98 - 77.53
  From
31-Dec-2019
To
31-Dec-2020
From
31-Dec-2020
To
31-Dec-2021
From
31-Dec-2021
To
31-Dec-2022
From
31-Dec-2022
To
31-Dec-2023
From
31-Dec-2023
To
31-Dec-2024
Total Return (%)

as of 31/Dec/2024

15.53 16.94 -5.29 -0.96 -1.05
Constraint Benchmark 1 (%)

as of 31/Dec/2024

13.52 19.80 -5.41 3.76 1.13

The figures shown relate to past performance. Past performance is not a reliable indicator of future performance. Markets could develop very differently in the future. It can help you to assess how the fund has been managed in the past

Share Class and Benchmark performance displayed in CNH, hedged share class benchmark performance is displayed in USD.

Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: Blackrock

Key Facts

Key Facts

Net Assets of Fund
as of 21/Jan/2025
USD 13,484,172,806
Fund Launch Date
06/Apr/2001
Fund Base Currency
USD
Constraint Benchmark 1
MSCI World Health Care Index
SDR classification
Overseas ESG - out of scope
Ongoing Charges Figures
1.78%
ISIN
LU1254117382
Use of Income
Accumulating
Regulatory Structure
UCITS
Morningstar Category
Other Equity
Dealing Frequency
Daily, forward pricing basis
SEDOL
BYM6PT7
Share Class launch date
15/Jul/2015
Share Class Currency
CNH
Asset Class
Equity
SFDR Classification
Article 8
Initial Charge
5.00%
Management Fee
1.50%
Performance Fee
0.00%
Domicile
Luxembourg
Management Company
BlackRock (Luxembourg) S.A.
Dealing Settlement
Trade Date + 3 days
Bloomberg Ticker
BGWHA2C

Portfolio Characteristics

Portfolio Characteristics

Number of Holdings
as of 31/Dec/2024
83
3y Beta
as of 31/Dec/2024
0.888
P/B Ratio
as of 31/Dec/2024
5.06
Standard Deviation (3y)
as of 31/Dec/2024
12.97%
P/E Ratio
as of 31/Dec/2024
32.45

ESG Integration

ESG Integration

BlackRock considers many investment risks in our processes. In order to seek the best risk-adjusted returns for our clients, we manage material risks and opportunities that could impact portfolios, including financially material Environmental, Social and/or Governance (ESG) data or information, where available. See our Firm Wide ESG Integration Statement for more information on this approach and fund documentation for how these material risks are considered within this product, where applicable.

Sustainability-related Disclosure

Sustainability-related Disclosure

This section provides sustainability-related information about the Fund, pursuant to Article 10 SFDR.

Risk Indicator

Risk Indicator

1
2
3
4
5
6
7
Low Risk High Risk
Typically low rewards Typically high rewards

Holdings

Holdings

as of 31/Dec/2024
Name Weight (%)
ELI LILLY 7.55
BOSTON SCIENTIFIC CORP 5.75
ABBVIE INC 5.57
INTUITIVE SURGICAL INC 4.37
ASTRAZENECA PLC 4.01
Name Weight (%)
ABBOTT LABORATORIES 3.96
ROCHE HOLDING PAR AG 3.87
UNITEDHEALTH GROUP INC 3.64
SANOFI SA 3.25
JOHNSON & JOHNSON 2.72
Holdings subject to change

Exposure Breakdowns

Exposure Breakdowns

as of 31/Dec/2024

% of Market Value

as of 31/Dec/2024

% of Market Value

Show More
as of 31/Dec/2024

% of Market Value

as of 31/Dec/2024

% of Market Value

Negative weightings may result from specific circumstances (including timing differences between trade and settle dates of securities purchased by the funds) and/or the use of certain financial instruments, including derivatives, which may be used to gain or reduce market exposure and/or risk management. Allocations are subject to change.

Pricing & Exchange

Pricing & Exchange

Portfolio Managers

Portfolio Managers

Erin Xie, PhD

 

Erin Xie, PhD, Managing Director and portfolio manager, is the head of the Health Sciences team, part of BlackRock’s Active Equity Group. She is the lead portfolio manager for the Health Sciences equity portfolios.

Xiang Liu, PhD

 

Xiang Liu, PhD, Managing Director and portfolio manager, is a member of the Health Sciences team, part of BlackRock’s Active Equity Group. He is co-portfolio manager for the Health Sciences equity portfolios and is responsible for coverage of the medical devices & supplies sector.